Quarterly report [Sections 13 or 15(d)]

BUSINESS COMBINATION (Details 1)

v3.25.1
BUSINESS COMBINATION (Details 1) - BioCorRx Pharmaceuticals, Inc [Member]
3 Months Ended
Mar. 31, 2025
Risk-free interest rate 3.96%
Expected term (years) 2 years
Expected volatility 161.00%
Expected dividends 0.00%